Date : June 20, 2018
If you take a good hard look at VBIO, you will see a stock that was a major momentum leader on the OTC back in December of 2016, and then went into a long consolidative funk. However, in recent action, the giant has awakened. And shorts are starting to run for the hills.
They don’t want to be caught on the tracks when another 500% freight train goes steaming up the line.
And there’s plenty of reason to worry if you’re betting against this one right now: the company has gotten in good with regulators and expanded its IP, all the while working to help end the devastating opioid epidemic in the US.
Shares have sparked a new upward trend to life, and with a tight float of just 18 million shares, momentum looks set to possibly feed on itself here in a big way.
Company: Vitality Biopharma Inc.
Latest News: http://finance.yahoo.com/q/h?s=VBIO+Headlines
Company Website: http://www.vitality.bio
Who is VBIO?
Vitality Biopharma Inc (OTCMKTS:VBIO) frames itself as a company that focuses on the development of cannabinoids for the treatment of neurological and inflammatory disorders, such as inflammatory bowel disease and multiple sclerosis in the United States. VBIO is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders.
Its products in the pipeline include Cannabosides – VITA-100 for gastrointestinal disorders, including inflammatory bowel disease and irritable bowel syndrome; Cannabosides – VITA-210 for muscle spasticity in multiple sclerosis and rare white matter disorders; and Cannabosides for epilepsy, schizophrenia, substance abuse, and Huntington’s disease.
The company was formerly known as Stevia First Corp. and changed its name to Vitality Biopharma Inc. in July 2016. Vitality Biopharma, Inc. was founded in 2007 and is based Los Angeles, California.
According to company press materials, “Vitality Biopharma is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders.”
Vitality believes that its prodrug Cannabosides could enable targeted delivery of THC molecules into the gut, which would enable higher local concentrations for pain and inflammation in the gastrointestinal tract. The company plans to begin Phase I/II studies this year while taking pathways that involve shorter trials through acute dosing regimens.
Most recently, the company just announced that it has received approval from both the U.S. Drug Enforcement Administration (DEA) and the State of California Research Advisory Panel permitting the Company to continue development of its novel cannabinoid pharmaceutical prodrugs.
Robert Brooke, CEO and Co-founder of Vitality Biopharma adds that, “Our team first pioneered a novel biosynthesis process for our cannabinoid prodrugs, and now they’ve successfully scaled it in a way that could enable widespread supply for clinical trials and even commercialization. This puts us in an enviable position within our industry, and we look forward to seeing what else can be achieved in the months and year ahead.”
That is huge news because the company also just announced the discovery of new antimicrobial activity of cannabinoids and its application for treatment of C. difficile-associated diarrhea and colitis.
According to that release from last month, “Antibiotic-associated diarrhea and colitis has climbed markedly since the early 1980’s, and now the CDC estimates there are more than 2 million illnesses annually due to antibiotic resistance. Many of these severe infections are hospital-acquired and now known to be attributed to C. difficile, a pathogen that colonizes the gastrointestinal tract. C. difficile infections cause diarrhea and colitis and contributed to 29,000 deaths in the U.S. in 2015, primarily in sensitive elderly populations.”
Somewhere in between the two, the company took a leadership role in the fight against the opioid epidemic, leading a symposium early this month. That adds up to priceless public good will and terrific PR.
There is some real meat on the bone here, but the company has also managed to frame itself in a positive light time and time again in terms of public perception.
Traders should recall that this was one of the strongest stocks on the planet about eighteen months ago, when shares blasted off from well under a dollar to well over four bucks per share in about six weeks.
Since then, we have seen a lot of consolidation, with shares moving roughly sideways back and forth across the $1.50/share level. But recent action has started to get very interesting.
In late May, the stock broke sharply below multiyear support, diving under the $1.50/share level and nearly tagging support at the $1/share level. And then the bid came back: since that inflection the stock has been on fire yet again, ripping up of multi-month downtrend line, and breaking out above resistance at the 50-day simple moving average.
Volume has started to pick up and technical indications look very positive after the inflection off of the deeply oversold levels last month.
Has momentum been reborn here? Could we see the type of move we saw in late 2016 erupt again in VBIO?
VBIO (Vitality Biopharma Inc.) frames itself as a company that focuses on the development of cannabinoids for the treatment of neurological and inflammatory disorders, such as inflammatory bowel disease and multiple sclerosis in the United States.
VBIO is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. Its products in the pipeline include Cannabosides – VITA-100 for gastrointestinal disorders, including inflammatory bowel disease and irritable bowel syndrome; Cannabosides – VITA-210 for muscle spasticity in multiple sclerosis and rare white matter disorders; and Cannabosides for epilepsy, schizophrenia, substance abuse, and Huntington’s disease.
VBIO was founded in 2007 and is based Los Angeles, California.
- VBIO is a tight float stock (just 18M shares) that has a history of going on massive runs when momentum builds, as it has lately.
- VBIO is making real money, with trailing revs already coming in at $109K.
- VBIO just got word that it has been cleared to keep pushing the needle on its breakthrough cannabinoid prodrug technology.
- VBIO is coming off an RSI trough under 20, pointing to a massively oversold stock now heading back the other way.
- VBIO just recorded a MACD Bullish reversal and breakout, suggesting a technical change in trend.
VBIO has started to flash some major momentum signals once again. The last time we saw this stock engage with the market this way, it was headed another 500% higher in a matter of weeks.
Given the monster catalysts in play right now – including the company’s revolutionary prodrug breakthrough technology and its expanded intellectual property – a new burst of red hot momentum from current levels wouldn’t be the least bit surprising, especially when considering the tiny number of shares rattling around on the float in this stock at present.